Tags : canada

MedTech

Glaukos Expands its Partnership with Santen for Preserflo MicroShunt

Shots: The companies enter into a license agreement for the Preserflo MicroShunt superseding the previous collaboration between the two parties Glaukos get exclusive commercialization rights for the MicroShunt in the US, Australia, New Zealand, Canada, Brazil, Mexico and the remainder of Latin America and gain full control over all development activities for the MicroShunt in […]Read More

Biosimilars

Samsung Bioepis Expand its Footprints with the Launch of Hadlima

Shots: Samsung Bioepis in collaboration with Merck broadens its global reach by launching Hadlima in Australia for multiple autoimmune diseases With the launch in Australia, Samsung Bioepis’ adalimumab is now available in three markets: Europe, Canada, and Australia Hadlima is Samsung Bioepis’ third anti-TNF biosimilar launched in Australia, following the launch of Brenzys (etanercept) and […]Read More

Biosimilars

Fresenius Kabi Launches Idacio (biosimilar, adalimumab) for Multiple Chronic Inflammatory

Shots: Health Canada has authorized Idacio on Oct 30, 2020, for marketing in Canada and is now available for all indications of the reference (Humira) in the field of rheumatology, gastroenterology and dermatology Health Canada’s approval was based on analytical, pre/ clinical data that demonstrated similar PK, efficacy, safety and immunogenicity to the Humira. Idacio […]Read More

Biosimilars

Viatris Launches Hulio (biosimilar, adalimumab) in Canada

Shots: Health Canada has approved Hulio, a biosimilar referencing AbbVie’s Humira (adalimumab), which is now available in Canada. It is licensed from Fujifilm Kyowa Kirin and approved for all adalimumab indications The approval was based on an analytical, pre/ clinical program. Fujifilm Kyowa Kirin conducted a P-III ARABESC study that demonstrated no differences in terms […]Read More

Biosimilars

Sandoz Launches Hyrimoz (biosimilar, adalimumab) in Canada

Shots: The company expands its portfolio with the marketing of the 5th biosimilars in Canada. Hyrimoz is indicated for use in nine indications of the reference (Humira) in the field of rheumatology, gastroenterology and dermatology Sandoz Canada has completed the pCPA negotiations for Hyrimoz, which is the first step in securing public reimbursement Hyrimoz is […]Read More

Biosimilars

Sandoz to Launch Hyrimoz (biosimilar, adalimumab) in Canada

Shots: Health Canada has authorized Hyrimoz on Nov 4, 2020 for marketing in Canada. Hyrimoz has been approved for use in all same indications as reference Humira, including rheumatology, gastroenterology and dermatology A patient support program will be available to patients treated with Hyrimoz providing guidance with reimbursement navigation, financial assistance, administrative support & education […]Read More